This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Toa Eiyo Ltd.. Active years: 2020.
Company Filing History:
Years Active: 2020
Title: Fumito Maruyama: Innovator in Glaucoma Treatment
Introduction
Fumito Maruyama is a notable inventor based in Ota-ku, Japan. He has made significant contributions to the field of ophthalmology, particularly in the development of therapeutic agents for glaucoma. His innovative work has the potential to improve the quality of life for many individuals suffering from this condition.
Latest Patents
Maruyama holds a patent for a novel therapeutic agent for glaucoma. This agent is characterized by its sGC-activating action. The patent describes a therapeutic agent or ocular hypotensive agent that contains, as an effective component, a compound represented by Formula (I-a) or Formula (I-b). These compounds have a Log D value of more than 1.5 and less than 2.5, or a pharmaceutically acceptable salt thereof. This innovation represents a significant advancement in glaucoma treatment.
Career Highlights
Fumito Maruyama is associated with Toa Eiyo Ltd., where he continues to work on groundbreaking research and development in the pharmaceutical field. His dedication to innovation has led to the creation of effective solutions for complex medical issues.
Collaborations
Maruyama collaborates with talented individuals such as Toshihiro Sawabe and Akiyuki Takaya. These partnerships enhance the research and development process, fostering an environment of creativity and innovation.
Conclusion
Fumito Maruyama's contributions to glaucoma treatment through his patented therapeutic agent highlight his role as a key innovator in the field. His work not only showcases his expertise but also reflects the importance of collaboration in advancing medical science.